In recent years, the research and development of domestic innovative drugs has been hot, but the targets are piled up, the track is crowded, and the involution is serious, which has caused the development of the innovative drug industry to fall into a bottleneck period, coupled with the impact of medical insurance control fees, the epidemic and other factors, the investment and financing in the domestic medical and health field are "deserted"
compared with last year.
In the first half of 2022, the overall investment and financing trend in the medical and health field slowed down, and the total amount of financing and the number of financing events both decreased
.
Data show that in the first half of 2022, there were 632 investment and financing events in the medical and health field across the country, and the disclosed investment and financing amount was 115.
2 billion yuan
.
Specifically, in the first half of 2022, the number of investment and financing events in the primary market in China's medical and health sector decreased by 46.
7% year-on-year and 45.
9% month-on-month; The number of IPO events decreased by 45.
5% year-on-year and 55.
2% month-on-month.
The number of refinancing events in the secondary market decreased by 57.
8% year-on-year and 29.
6%
month-on-month.
According to other data, as of the end of August 2022, there were 1,117 investment and financing events in the primary market of China's medical and health field, a year-on-year decrease of 28%; The amount of investment and financing reached 101.
2 billion yuan, a year-on-year decrease of 38%; The average single transaction amount reached RMB91 million, a year-on-year decrease of 13.
3%.
Judging from the investment and financing events that occurred in the first eight months of the primary market, they mainly involved innovative drugs, medical devices and corporate services (CRO, CDMO, CMO, consulting services, marketing services, etc.
).
In the secondary market, the number of IPO events and the amount of funds raised in the first eight months also decreased significantly compared with last year, of which 45 IPO events occurred, mainly focusing on innovative drugs, medical devices and IVD tracks
.
From the perspective of popular investment tracks from January to August 2022, in the primary market, cell therapy, macromolecular innovative drugs, gene therapy and other subdivisions in the field of innovative drugs are still favored
.
Among them, the cell therapy track has attracted much attention
from capital.
Following the approval of Novartis and Kate's two CAR-T products in 2017, the number and amount of cell therapy investment and financing events have increased
rapidly.
In China, since 2020, Legend Biologics, Yongtai Biologics, JW Therapeutics, Genxi Biologics, Keji Pharmaceutical, etc.
have been listed successively, among which JW Therapeutics and Fosun Kite two CAR-T products were approved for listing in China in 2021, and Nanjing Legend's CAR-T was approved for listing in the United States and the European Union in 2022, further stimulating the enthusiasm for investment in
cell therapy in China.
At present, cell therapy has entered a new stage of development, and the industry generally believes that the new era of cell therapy has arrived, and the future of the entire market is promising
.
Gene therapy is a new generation of precision therapy after small molecule and large molecule targeted therapy, providing new treatment concepts and means for tumors, rare diseases, chronic diseases and other refractory diseases, with considerable market prospects, which has increased from $50 million in 2016 to $2.
075 billion in 2020, with an average annual compound growth rate of nearly 154%, and is expected to reach nearly $6.
6 billion
in 2022.
In recent years, cell and gene therapy has become one of the most eye-catching emerging areas in the global biotechnology field, and as a result, it continues to receive significant investment
from investors and biopharmaceutical companies.
Data shows that from 2016 to 2020, the total financing of the global gene therapy industry has increased significantly from $5.
22 billion to $19.
9 billion, with an average annual compound growth rate of nearly 40%.
In addition to the innovative drug segment, from January to August 2022, the number and amount of surgical instruments, medical robots and other subdivisions on the medical device track, as well as the early screening of diseases on the genetic testing track, are also relatively high
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
